- Anavex Life Sciences' (NASDAQ:AVXL) oral drug candidate blarcamesine (ANAVEX2-73) slowed cognitive decline in a phase 2b/3 study.
- Shares are up ~3% in Thursday premarket trading.
- The trial was conducted in ~500 participants with early symptoms of Alzheimer's, including mild cognitive impairment and mild dementia. Patients were randomized to receive blarcamesine or placebo once daily over 48 weeks.
- Results showed clinically significant differences in ADAS-Cog13 and CDR-SB, two Alzheimer's disease assessment scales, between the treatment and placebo arms.
- In addition, biomarkers of amyloid beta, a plaque found in the brains of those with Alzheimer's, indicated anti-amyloid effects of blarcamesine. Also, brain MRIs showed a significant reduction in brain volume loss in the blarcamesine-treated group.
- Anavex (AVXL) said that blarcamesine "restores cellular homeostasis by targeting sigma-1 and muscarinic receptors."
More good news
Add CGS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.24 |
Change
-0.035(2.76%) |
Mkt cap ! $210.9M | |||
| Open | High | Low | Value | Volume |
| $1.20 | $1.24 | $1.17 | $735.3K | 592.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10551 | $1.23 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.24 | 2569 | 1 |
View Market Depth
| Last trade - 16.10pm 25/07/2024 (20 minute delay) ? |
| CGS (ASX) Chart |